Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca : Emergent plans to fix issues that halted vaccine production early as July -U.S. House memo

05/19/2021 | 11:44am EDT

May 19 (Reuters) - Emergent BioSolutions Inc told U.S. regulators it aims as soon as July to correct the problems at its manufacturing facility that ruined millions of COVID-19 vaccine doses, according to a private correspondence published by the U.S. House Oversight Committee.

Emergent Executive Chairman Fuad El-Hibri was repeatedly questioned at a Wednesday Congressional hearing about his ties to the Trump administration. An official under former President Donald Trump who oversaw the U.S. government's vaccine deal with Emergent had previously received consulting fees from the company, the U.S. House memo said.

El-Hibri said it was "simply not true" that his relationship with Trump official Robert Kadlec influenced the U.S. government's contract award.

The U.S. Food and Drug Administration paused production of Johnson & Johnson vaccines at Emergent's Baltimore plant in April after an inspection flagged numerous serious quality control and sanitary issues.

The company contaminated millions of vaccine doses during multiple incidents in 2020 and 2021, the memo said.

Emergent shares were down nearly 3% to $56.42 in midday trading, while J&J shares were off less than 1%.

Emergent CEO Robert Kramer said at the hearing that he "can't specifically comment" on the total number of COVID-19 vaccine doses that were ruined at the Baltimore facility.

However, Kramer said in March that material for 15 million J&J doses was ruined. He also said "a number" of batches of AstraZeneca's COVID-19 vaccine were ruined in early production ramp ups.

The company expects to complete corrective measures such as retraining its staff and acquiring additional refrigerators by as early as July, according to the correspondence.

It is unclear whether Emergent can begin manufacturing more COVID-19 vaccine before correcting all the issues flagged by U.S. regulators.


Emergent had not previously disclosed a timeline for resuming vaccine production. In a late April investor call, Kramer said he is "hopeful that we can soon return to producing tens of millions of doses per month."

Staff working for the government's Operation Warp Speed program in June 2020 flagged "significant" personnel issues at Emergent's Maryland plant, including that "the staffing plans presented seem inadequate" to produce three products, according to a draft report cited in the memo.

The report said recent audits, including one by the FDA, "highlighted the need for extensive training of personnel."

The memo also said Emergent executives gave themselves millions of dollars in bonuses in 2020 despite knowing that their facilities were ruining batches of COVID-19 vaccines.

J&J's vaccine was contaminated with ingredients from AstraZeneca's shot, which was also being produced at the plant at the time. Production of AstraZeneca's vaccine was subsequently moved elsewhere and manufacture of J&J's one-shot vaccine was halted there after the FDA inspection.

"At the same time that the company was destroying millions of vaccine doses... its executives were cashing out," said U.S. Congresswoman Carolyn Maloney, a Democrat.

Kramer said the U.S. government contracted with Emergent in 2012 to help it prepare for public health emergencies, but failed to provide the financial support needed to boost capacity ahead of the pandemic.

U.S. government funding "persistently fell short of what was needed to reach full operating potential," Kramer said in his opening remarks to the Congressional committee.

"As a result, at the end of 2019, (the Baltimore plant) had roughly 100 employees," and was less than a year away from being charged with making millions of COVID-19 shots, the CEO said.

(Reporting by Carl O'Donnell; Editing by Jonathan Oatis and Bill Berkrot)

© Reuters 2021
All news about ASTRAZENECA PLC
02:40pPFIZER : Brazil reopens amid looming threat from delta variant
02:10pRelaxed Border Restrictions For U.S. Travelers Coming August 9, 2021
01:55pCORONAVIRUS – TUNISIA : Belgium sends emergency aid to Tunisia in the figh..
08:28aASTRAZENECA : Secures FDA Approval for Bydureon BCise Injectable Suspension for ..
06:26aAstraZeneca's Bydureon BCise Gets U.S. Approval For Type 2 Diabetes in Pediat..
05:06aCORRECTION : AstraZeneca Says Data Shows One Dose of COVID-19 Jab 'Highly Effect..
04:48aASTRAZENECA : Single-Dose COVID-19 Jab Shows Effect Against Beta, Gamma, Delta V..
04:43aAstraZeneca's Covid-19 Vaccine Effective Against Variants After One Dose, Can..
04:31aT&T GROUP : Le gouvernement vietnamien soutient T&T Group pour l'achat de 40 mil..
04:08aASTRAZENECA : Vaxzevria is highly effective after one dose against severe diseas..
More news
Financials (USD)
Sales 2021 31 752 M - -
Net income 2021 4 669 M - -
Net Debt 2021 10 816 M - -
P/E ratio 2021 33,0x
Yield 2021 2,42%
Capitalization 181 B 181 B -
EV / Sales 2021 6,04x
EV / Sales 2022 5,26x
Nbr of Employees 76 100
Free-Float 81,1%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 27
Last Close Price 116,50 $
Average target price 132,19 $
Spread / Average Target 13,5%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC15.50%155 197
JOHNSON & JOHNSON8.01%432 430
ROCHE HOLDING AG11.02%325 975
PFIZER, INC.12.66%218 198
NOVARTIS AG0.20%207 246